ArticleBMC medical genomics2025
Genomic surveillance and phylo-evolutionary analysis of SARS-CoV-2 variants in Osun state, Nigeria during the second wave of COVID-19 pandemic.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSARS-CoV-2 genome sequencing, genomic characterization, and global data sharing are recommended to facilitate countermeasures against COVID-19. This study involved whole genome sequencing and phylo-evolutionay analysis of SARS-CoV-2 variants circulating in Osun State, Nigeria between January and June, 2021.
methodsIn the present retrospective, molecular epidemiologic study, a total of 60 nasopharyngeal samples from RT-qPCR-positive COVID-19 patients originating from eight study locations were analyzed. This was done using RNA extraction application of the McKinsey Global Institute’s (MGI) DNBSEQ-G50RS high-throughput genome Sequencing Technology and Bioinformatics Analysis Pipeline. Quantitative data were analyzed with descriptive and inferential statistics.
resultsForty-five SARS-CoV-2 (45/60) whole genome sequences (WGSs) were successfully analyzed with participants being mostly male adults (64.4%) and a median age of 44 years. Five PANGO lineages including: B (35.6%), B.1.525 (31.1%), B.1.1.7 (28.9%), B.1 (2.2%), and L.3 (2.2%) were identified, with Eta VOI (14/45) and Alpha VOC (13/45) as the dominant variants. A total of 29/45 of these genomes exhibited amino acid (aa) substitutions in the viral spike (S) protein, totaling 275 substitutions. Six of these genome sequences carried key mutations, including H69del, V70del, Y144del, D614G, N501Y, A570D, P681H, T716I, and Q677H. These mutations are known to influence SARS-CoV-2 transmissibility, virulence, and potential resistance to neutralization by vaccine-induced antibodies/convalescent sera. Phylo-evolutionary analysis revealed three distinct clusters, 16 sequences from Lineage B clustered closely with the reference Wuhan-Hu-1 strain (NC_045512.2). Notably, 19 of our WGSs showed genomic relatedness to SARS-CoV-2 strains from other regions of Nigeria, as well as, from West/other African countries, including Egypt, Senegal, Morocco and South Africa. The single L.3 lineage reported clustered with strains from Nigeria and Benin.
conclusionsThese evidences suggest inbound or outbound transmission of the dominant Eta and Alpha variants. The study highlights the dominance of Eta VOIs and Alpha VOCs during the second COVID-19 wave in Osun State, Nigeria, suggesting potential inbound and outbound spread of the virus between other states in Nigeria and other African countries. The general absence of severe illness (except for four participants with shortness of breath) among study participants may indicate a protective effect of post-exposure immune response; however, underreporting of severe cases cannot be ruled out as a potential contributing factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.